PixarBio hopes to have an FDA-approved, non-addictive pain treatment that would offer a viable alternative to morphine by 2018. The company is reverse merging…

Partners Eli Lilly and AstraZeneca got a leap ahead in the BACE inhibitor race as they secure a fast-track designation from the FDA for Phase III candidate…

Portola Pharmaceuticals had expected to launch its first drug this year. But those plans have been pushed back as its lead candidate Andexxa, developed to…

Johnson & Johnson and Genmab have passed another milestone on the route to FDA approval of Darzalex as a second-line combination treatment for multiple…

Aurinia Pharmaceuticals has posted positive new data for its experimental drug voclosporin for active lupus nephritis--but 12 deaths in the study's…

Heron Therapeutics has gained an FDA approval for its long-acting, anti-nausea drug Sustol. This comes after about 6 years of regulatory back-and-forth.

Gene therapy biotech Spark Therapeutics has posted new long-term data for its Phase III trial of voretigene neparvovec, an experimental treatment for patients…

Investors knocked a few percentage points off Amarin’s share price after the firm added a second interim analysis to its Phase III cardiovascular disease trial…